

Cardio-Oncology Suggested Reading

Guideline/Position Statements

1. **ESMO 2012:** Curigliano, G., et al., *Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines*. Ann Oncol, 2012. **23 Suppl 7:** p. vii155-66.
2. **AHA 2013:** Lipshultz, S.E., et al., *Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association*. Circulation, 2013. **128(17):** p. 1927-95.
3. **ASE 2014:** Plana, J.C., et al., *Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging*. J Am Soc Echocardiogr, 2014. **27(9):** p. 911-39
4. **ESC 2016:** Zamorano, J.L., et al., *2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)*. Eur Heart J, 2016. **37(36):** p. 2768-2801.
5. **ASCO 2017:** Armenian, S.H., et al., *Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline*. J Clin Oncol, 2017. **35(8):** p. 893-911.

Reviews

1. Barac, A., et al., *Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next Level*. J Am Coll Cardiol, 2015. **65(25):** p. 2739-46.
2. Hahn, V.S., D.J. Lenihan, and B. Ky, *Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies*. J Am Heart Assoc, 2014. **3(2):** p. e000665.
3. van Dalen, E.C., et al., *Cardioprotective interventions for cancer patients receiving anthracyclines*. Cochrane Database Syst Rev, 2011(6): p. Cd003917.
4. Kalam, K. and T.H. Marwick, *Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis*. Eur J Cancer, 2013. **49(13):** p. 2900-9.

Local Expert Reviews

1. Krone, R., [Protecting the heart in cancer patients: The Role of Cardio-Oncology](#). EMJ Cardiol. 2017;5[1]:47-52.

Screening

1. Walker, J., et al., *Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging*. J Clin Oncol, 2010. **28(21):** p. 3429-36.

2. Cardinale, D., et al., *Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy*. *Circulation*, 2015. **131**(22): p. 1981-8.
3. Lancellotti, P., et al., *Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography*. *J Am Soc Echocardiogr*, 2013. **26**(9): p. 1013-32

Cardiotoxicity, Risk Factors and Risk Prediction

1. van Nimwegen, F.A., et al., *Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk*. *JAMA Intern Med*, 2015. **175**(6): p. 1007-17.
2. Armenian, S.H., et al., *Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study*. *J Clin Oncol*, 2016. **34**(10): p. 1122-30.
3. Armenian, S.H., et al., *Late congestive heart failure after hematopoietic cell transplantation*. *J Clin Oncol*, 2008. **26**(34): p. 5537-43.
4. Chow, E.J., et al., *Individual prediction of heart failure among childhood cancer survivors*. *J Clin Oncol*, 2015. **33**(5): p. 394-402.
5. Ezaz, G., et al., *Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer*. *J Am Heart Assoc*, 2014. **3**(1): p. e000472
6. Hershman, D.L., et al., *Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma*. *J Clin Oncol*, 2008. **26**(19): p. 3159-65.
7. Chavez-MacGregor, M., et al., *Trastuzumab-related cardiotoxicity among older patients with breast cancer*. *J Clin Oncol*, 2013. **31**(33): p. 4222-8
8. Slamon, D., et al., *Adjuvant trastuzumab in HER2-positive breast cancer*. *N Engl J Med*, 2011. **365**(14): p. 1273-83.
9. Heinzerling, L., et al., *Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy*. *J Immunother Cancer*, 2016. **4**: p. 50.
10. Curigliano, G., et al., *Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management*. *CA Cancer J Clin*, 2016. **66**(4): p. 309-25.
11. Johnson, D.B., et al., *Fulminant Myocarditis with Combination Immune Checkpoint Blockade*. *N Engl J Med*, 2016. **375**(18): p. 1749-1755.
12. Chen, J., et al., *Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer*. *J Am Coll Cardiol*, 2012. **60**(24): p. 2504-12

Prevention/Cardio-protection

1. Acar, Z., et al., *Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy*. *J Am Coll Cardiol*, 2011. **58**(9): p. 988-9.
2. Gulati, G., et al., *Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol*. *Eur Heart J*, 2016. **37**(21): p. 1671-80.

3. Bosch, X., et al., *Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (prevention of left Ventricular dysfunction with Enalapril and carvedilol in patients submitted to intensive Chemotherapy for the treatment of Malignant hemopathies)*. J Am Coll Cardiol, 2013. **61**(23): p. 2355-62.
4. Georgakopoulos, P., et al., *Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up*. Am J Hematol, 2010. **85**(11): p. 894-6.
5. Kaya, M.G., et al., *Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study*. Int J Cardiol, 2013. **167**(5): p. 2306-10.
6. Pituskin, E., et al., *Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity*. J Clin Oncol, 2017. **35**(8): p. 870-877.
7. Akpek, M., et al., *Protective effects of spironolactone against anthracycline-induced cardiomyopathy*. Eur J Heart Fail, 2015. **17**(1): p. 81-9.
8. Seicean, S., et al., *Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study*. J Am Coll Cardiol, 2012. **60**(23): p. 2384-90.
9. Nielsen, S.F., B.G. Nordestgaard, and S.E. Bojesen, *Statin use and reduced cancer-related mortality*. N Engl J Med, 2012. **367**(19): p. 1792-802

Treatment

1. Cardinale, D., et al., *Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy*. J Am Coll Cardiol, 2010. **55**(3): p. 213-20
2. Cardinale, D., et al., *Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy*. Circulation, 2015. **131**(22): p. 1981-8.

Radiation Therapy

1. Taylor, C.W., et al., *Exposure of the Heart in Breast Cancer Radiation Therapy: A Systematic Review of Heart Doses Published During 2003 to 2013*. Int J Radiat Oncol Biol Phys, 2015. **93**(4): p. 845-53.
2. Groarke, J.D., et al., *Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease*. Eur Heart J, 2014. **35**(10): p. 612-23.
3. Illidge, T., et al., *Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group*. Int J Radiat Oncol Biol Phys, 2014. **89**(1): p. 49-58